Comparative Pharmacology
Head-to-head clinical analysis: KOMBIGLYZE XR versus SAXAGLIPTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KOMBIGLYZE XR versus SAXAGLIPTIN.
KOMBIGLYZE XR vs SAXAGLIPTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KOMBIGLYZE XR is a combination of saxagliptin, a DPP-4 inhibitor, and metformin, an AMPK activator. Saxagliptin increases incretin levels (GLP-1, GIP) by inhibiting DPP-4, leading to increased insulin release and decreased glucagon secretion. Metformin decreases hepatic gluconeogenesis and increases peripheral insulin sensitivity.
Saxagliptin is a selective, reversible inhibitor of dipeptidyl peptidase-4 (DPP-4), which prolongs the action of incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby enhancing glucose-dependent insulin secretion and suppressing glucagon release.
One tablet orally once daily with food; available strengths: saxagliptin 5 mg/metformin extended-release 500 mg, saxagliptin 5 mg/metformin extended-release 1000 mg. Titrate based on glycemic response and tolerability.
2.5 mg or 5 mg orally once daily irrespective of meals.
None Documented
None Documented
Clinical Note
moderateSaxagliptin + Gatifloxacin
"Saxagliptin may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateSaxagliptin + Rosoxacin
"Saxagliptin may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateSaxagliptin + Levofloxacin
"Saxagliptin may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateSaxagliptin + Trovafloxacin
"Saxagliptin may increase the hypoglycemic activities of Trovafloxacin."
Terminal elimination half-life for saxagliptin is 2.5 hours and for its active metabolite is 3.1 hours; clinical context: no significant accumulation at steady state.
Terminal half-life: 2.5 hours; accounts for DPP-4 inhibition duration despite rapid clearance.
Renal excretion of unchanged saxagliptin (24%) and its active metabolite 5-hydroxy saxagliptin (22%); fecal excretion of parent (0.3%) and metabolite (6%); total renal elimination accounts for approximately 75% of the administered dose.
Renal (75% as unchanged drug and metabolites; 25% as unchanged drug in urine) and fecal (22% as metabolites).
Category C
Category A/B
DPP-4 Inhibitor + Biguanide Combination
DPP-4 Inhibitor